Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDTCompany ParticipantsBassil Dahiyat - Co-Founder, ...

In second- or later-line setting, combination cut risk of disease progression or death by ...

BioAtla, Inc. (NASDAQ: BCAB or the "Company"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...

BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3Data highlight the potential of this ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.

MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...